Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

RCBF-quantification with 99mTc-HMPAO-SPECT: Theory and first results

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The activity concentrations of 99mTc-HMPAO in brain after intravenous injection were evaluated in 25 patients using SPECT. With additional first pass studies of heart and brain with the short lived isotope 195mAu, the cardiac output and the mean cerebral transit times of the patients were measured a short time before the HMPAO injection. The time dependence of 99mTc-HMPAO activity in the brain was registered during the first 5 min after injection over both hemispheres. Using a simplified three compartment model it was possible to calculate the mean retention fraction of HMPAO in brain from the time activity curves. It could be shown that the regional cerebral blood flow in ml/min per 100 g can be calculated from the activity concentration of HMPAO in the brain, the cardiac output and the retention fraction. In 15 of the 25 cases the rCBF was measured using the planar 133Xe inhalation method as a reference. We found a significant correlation between the mean hemisphere CBF from our method and the mean hemisphere grey matter CBF from the Xenon method with a correlation coefficient of 0.73.

This is a preview of subscription content, log in to check access.

References

  1. Andersen AR, Friberg H, Lassen NA, Kristensen K, Neirinckx RD (1987) Serial studies of cerebral blood flow using 99m-Tc-HMPAO: a comparison with 133 Xe. Nucl Med Comm 8:549–557

  2. Büll U, Stirner H, Braun H, Kreiten K, Ferbert A (1987) SPECT with 99m-Tc-HMPAO and 99m-Tc-pertechnetate to assess regional cerebral blood flow (rCBF) and blood volume (rCBV). Preliminary results in cerebrovascular disease and interictal epilepsy. Nucl Med Comm 8:519–524

  3. Costa DC, Ell PJ, Cullum ID, Jarritt PH (1986) The in-vivo distribution of 99m-Tc-HMPAO in normal man. Nucl Med Comm 7:647–658

  4. Costa DC, Jones BE, Steiner TJ, Aspey BS, Ell PJ, Cullum I, Jewkes RF (1986) Experimental studies of Tc-99m HM-PAO with an rCBF model. Nucl Med Comm 7:282–283

  5. Gruner KR (1986) Die Entwicklung heutiger Radiopharmaka aus der Sicht des Herstellers. Der Nuklearmediziner 9:297–315

  6. Kircos LT, Carey JE, Keyes JW (1987) Quantitative organ visualization using SPECT. J Nucl Med 28:334–341

  7. Kuhl DE, Barrio JR, Huang SC, Selin C, Ackermann RF, Lear JL, Wu JL, Phelps ME (1982) Quantifying local cerebral blood flow by N-Isopropyl-p-123-I-Iodoamphetamine (IMP) tomography. J Nucl Med 23:196–203

  8. Larsson S (1980) Gamma camera emission tomography. Acta Radiologica Supplementum 363, Stockholm

  9. Lassen NA, Andersen AR, Neirinckx RD, Ell PJ, Costa DC (1987) Validation of Ceretec. In: Ell PJ (ed) The clinical application of rCBF imaging by SPECT. Amersham International, Amersham, p 14

  10. Leonard J-P, Nowotnik DP, Neirinckx RD (1986) Technetium-99m-d, 1-HM-PAO: A new radiopharmaceutical for imaging regional brain perfusion using SPECT — A comparison with Iodine-123 HIPDM. J Nucl Med 27:1819–1823

  11. Meili A, Seelentag WW, Bekier A (1986) Die cerebrale 99m-Tc-Hexamethyl-Propylenaminoxim-Speicherung in Beziehung zu individuellen Faktoren wie Alter, Größe und Gewicht. Nucl Compact 17:334–336

  12. Msaki P, Axelsson B, Dahl CM, Larsson SA (1987) Generalized scatter correction method in SPECT using point scatter distribution functions. J Nucl Med 28:1861–1869

  13. Neirinckx RD (1987) Trapping mechanisms of HM-PAO. Symposium of the Rheinisch-Westfälische Gesellschaft für Nulearmedizin, Bonn

  14. Neirinckx RD, Nowotnik DP, Pickett RD, Harrison RC, Ell PJ (1987) Development of a lipophilic 99m-Tc complex useful for brain perfusion evaluation with conventional SPECT imaging equipment. In: Biersack HJ, Winkler C (eds) Amphetamines and pH-shift agents for brain imaging: basic research and clinical results. De Gruyter, Berlin-New York, p 59

  15. Nickel O, Schad N, Andrews EJ, Fleming JW, Mello M (1982) Scintigraphic measurement of left ventricular volumes from the count-density distribution. J Nucl Med 23:404–410

  16. Nickel O, Roesler A, Eißner D, Ulrich P, Lindner P, Hahn K (1987) Erste klinische Ergebnisse zur rCBF-Quantifizierung mit 99mTc-HMPAO-SPECT. Nucl Compact 18:35–38

  17. Obrist WD, Thompson HK, King CD, Wang HS (1967) Determination of regional cerebral blood flow by inhalation of 133-Xenon. Circ Res 20:124–135

  18. Schulthess GK, Ketz E, Schubiger PA, Bekier A (1985) Regional quantitative noninvasive assessment of cerebral perfusion and function with N-Isopropyl-123-I-p-Iodoamphetamine. J Nucl Med 26:9–16

  19. Sharp PF, Smith FW, Gemmell HG, Lyall D, Evans NTS, Gvozdanovic D, Davidson J, Tyrrell DA, Pickett RD, Neirinckx RD (1986) Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: Human volunteer studies. J Nucl Med 27:171–177

  20. Sorenson JA (1974) Quantitative measurement of radioactivity in vivo by whole-body counting. In: Hine GJ, Sorenson JA (eds) Instrumentation in Nuclear Medicine, vol. 2. Academic Press, New York, pp 311–348

Download references

Author information

Correspondence to O. Nickel.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nickel, O., Nägele-Wöhrle, B., Ulrich, P. et al. RCBF-quantification with 99mTc-HMPAO-SPECT: Theory and first results. Eur J Nucl Med 15, 1–8 (1989). https://doi.org/10.1007/BF00253591

Download citation

Key words

  • Cerebral blood flow
  • 99mTc-HMPAO
  • 195mAu
  • SPECT
  • Three compartment model
  • Uptake kinetics